Biogen Inc.: Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting
TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts